Adrastea starts new assignment with AstraZeneca

We are excited to start our first assignment with the global pharmaceutical AstraZeneca via the Barton Partnership. In our initial 3-month mandate, we will provide management services to AstraZeneca's transformation projects of its R&D clinical operations.

With a market capitalization of $232bn as of May 11, AstraZeneca is Britain's most valuable public company. AstraZeneca researches, manufactures, and sells pharmaceutical and medical products. It focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.

AstraZeneca's recent R&D successes include: Tagrisso, a medication used to treat non-small cell lung cancer; Farxiga, a medication to treat type 2 diabetes; and Vaxzevria, a vaccine against coronavirus.